Innovative nanobiotechnology for multiple myeloma treatment

The second most common cancer in the hematologic (blood) cancer category is multiple myeloma. It accounts for about 13% of all cases of blood cancer. 63% of multiple myeloma patients are older than 65, and the median age at diagnosis is 69. Plasma cells, which are produced from B-cells, are significantly increased in multiple myeloma. This process produces long-lived plasma cells in healthy humans, which are necessary to maintain the immune system's generation of polyclonal antibodies. On the other hand, monoclonal immunoglobulins or light chains are secreted in excess by clonal plasma cells in multiple myeloma. The common clinical symptoms of multiple myeloma, such as anemia, bone lesions, immunological suppression, elevated calcium levels, and renal dysfunction, are mostly caused by the buildup of clonal plasma cells in the bone marrow and the production of monoclonal protein. Since they offer a very effective and focused therapeutic approach, therapeutic agent-carrying multiple myeloma-targeted nanoparticles have garnered a lot of attention in this area. Nanoparticles have extensive potential applications as biomedical carriers in multiple myeloma therapy because of their prolonged circulation time, storage stability, ease of functionalization, ability to co-load several chemotherapeutic drugs, and efficient penetration into the bone marrow microenvironment. The application and modification of nanoparticles used to target multiple myeloma are the special focus of this problem.To further understand the limitations of multiple myeloma nano-formulations, we encourage publications of full articles, reviews, and communications on the following topics, among others:- Utilizing targeting nanomedicine to evaluate the results of treatment - Immunotherapy developments for multiple myeloma- Nano-pharmaceutics, pharmacodynamics, and nutraceuticals for multiple myeloma- Nanomedicine (Passive and active targeting therapies) for the delivery of proteins, nucleotides, and anticancer medications for imaging and therapy- Evaluation of the cytotoxicity of nanoparticles - Signalling pathway and nanomedicine- Inflammation and cytokines Topic editors: Nemany A.N. Hanafy, Devrim Gozuacik, Safacan Kolemen Source: https://www.frontiersin.org/research-topics/79984/innovative-nanobiotechnology-for-multiple-myeloma-treatment